Total value in 2020: $70.08M

Company Partner Amount ($M) Details Date

February - $34.08M

Aduro Biotech Inc. (Berkeley, Calif.) Merck & Co. Inc. (Kenilworth, N.J.) $10.00 Aduro Biotech earned a $10M development milestone payment from Merck following the start of a phase II trial of MK-5890 in non-small-cell lung cancer 2/7/20
Basilea Pharmaceutica Ltd. (Basel, Switzerland) Pfizer Inc. (New York) N/A Pfizer launched its antifungal Cresemba (isavuconazole) in Australia, triggering the first milestone payment related to Asia-Pacific territory to Basilea Pharmaceutica 2/28/20
Cytomx Therapeutics Inc. (South San Francisco) Bristol-Myers Squibb Co. (New York) $10.00 Cytomx Therapeutics advanced anti-CLTA4 Probody BMS-986249 into the phase II cohort of phase I/IIa study triggering a milestone payment of $10M from Bristol-Myers Squibb 2/24/20
Molecular Templates Inc. (Austin, Texas) Takeda Pharmaceutical Co. Ltd. (Osaka, Japan) $10.00 Molecular Templates to receive a $10M milestone payment from Takeda Pharmaceutical triggered by the start of dosing of a phase I study testing TAK-169 in patients with relapsed or refractory multiple myeloma 2/20/20
Oncodesign SA (Dijon, France) Servier SAS (Paris) $1.08 Servier and Oncodesign reached milestone in their strategic partnership on research and development of drug candidates for Parkinson’s disease triggering a success payment of €1M ($1.08M) 2/18/20
Summit Therapeutics plc (Oxford U.K.) Eurofarma Laboratórios SA (Sao Paulo, Brazil) $1.00 Summit Therapeutics achieved the initial enrollment target at sites in Latin America for phase III trials of ridinilazole to treat Clostridium difficile infection, triggering its first milestone payment of $1M from Eurofarma Laboratórios 2/6/20
Undisclosed pharma partner Arecor Ltd. (Cambridge, U.K.) N/A Arecor achieved a second milestone with an undisclosed pharma partner triggering a second milestone payment under terms of an exclusive global, royalty-bearing license agreement executed in October 2017 2/25/20
Vivus Inc. (Campbell, Calif.) Alvogen Korea Holdings Ltd. (Korea) $2.00 Vivus and Alvogen Korea Holdings launched Qsymia (phentermine and topiramate extended release) in South Korea triggering a $2M payment to Vivus 2/19/20

No Comments